Sofosbuvir is a nucleotide analog polymerase inhibitor, the first FDA-approved all-oral treatment for patients with HCV genotypes 2 or 3.
The drug received approval shortly after simeprevir, an Olysio, Janssen Therapeutics drug for patients with HCV genotype 1.
Sofosbuvir is a product of Gilead Sciences.
More Articles on Supply Chain:
FDA Gives 510(k) Clearance to Therapy Cool Flex Ablation Catheter
FDA Issues Draft Guidance on Custom Device Exemption Implementation
FDA Approves First Gel Sealant for Leaking Cornea After Cataract Surgery
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.